JP2020527173A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527173A5 JP2020527173A5 JP2020523052A JP2020523052A JP2020527173A5 JP 2020527173 A5 JP2020527173 A5 JP 2020527173A5 JP 2020523052 A JP2020523052 A JP 2020523052A JP 2020523052 A JP2020523052 A JP 2020523052A JP 2020527173 A5 JP2020527173 A5 JP 2020527173A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- group
- fluorophenyl
- optionally
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3-Amino-6-phenylpyridin-2-yl Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000005842 heteroatoms Chemical group 0.000 claims 7
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 102000004965 antibodies Human genes 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000007538 Neurilemmoma Diseases 0.000 claims 3
- 206010039667 Schwannoma Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960003966 nicotinamide Drugs 0.000 claims 2
- 235000005152 nicotinamide Nutrition 0.000 claims 2
- 239000011570 nicotinamide Substances 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 1
- 101700064281 ATP1 Proteins 0.000 claims 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 102100007290 CD274 Human genes 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- 208000009267 Cystic Kidney Disease Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010013663 Drug dependence Diseases 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- 208000001914 Fragile X Syndrome Diseases 0.000 claims 1
- 108009000484 Fragile X Syndrome Proteins 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 108010089187 Ipilimumab Proteins 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000008166 Kennedy's disease Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 claims 1
- 208000003002 Lymphoma, T-Cell, Peripheral Diseases 0.000 claims 1
- 206010061282 Meningeal neoplasm Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 210000003205 Muscles Anatomy 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 229960002715 Nicotine Drugs 0.000 claims 1
- 208000006660 Niemann-Pick Disease Diseases 0.000 claims 1
- 108010019706 Nivolumab Proteins 0.000 claims 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 1
- 210000000278 Spinal Cord Anatomy 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 229960004528 Vincristine Drugs 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000001861 immunosuppresant Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 201000005962 mycosis fungoide Diseases 0.000 claims 1
- 229930015196 nicotine Natural products 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000010133 oligodendroglioma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000007923 peripheral T-cell lymphoma Diseases 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 201000008839 post-traumatic stress disease Diseases 0.000 claims 1
- 229960000624 procarbazine Drugs 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17382447.5 | 2017-07-10 | ||
EP17382447 | 2017-07-10 | ||
PCT/ES2018/070491 WO2019012172A1 (es) | 2017-07-10 | 2018-07-09 | Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2) |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020527173A JP2020527173A (ja) | 2020-09-03 |
JP2020527173A5 true JP2020527173A5 (pt-PT) | 2021-04-15 |
JP7026787B2 JP7026787B2 (ja) | 2022-02-28 |
Family
ID=59315557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020523052A Active JP7026787B2 (ja) | 2017-07-10 | 2018-07-09 | ヒストン脱アセチル化酵素1および/または2(hdac1-2)の選択的阻害剤としての新規なヘテロアリールアミド誘導体 |
Country Status (21)
Country | Link |
---|---|
US (1) | US11241428B2 (pt-PT) |
EP (1) | EP3653620B9 (pt-PT) |
JP (1) | JP7026787B2 (pt-PT) |
KR (1) | KR102574135B1 (pt-PT) |
CN (1) | CN111051300B (pt-PT) |
AU (1) | AU2018300123B2 (pt-PT) |
BR (1) | BR112020000564A2 (pt-PT) |
CA (1) | CA3069273A1 (pt-PT) |
DK (1) | DK3653620T3 (pt-PT) |
EA (1) | EA039144B1 (pt-PT) |
ES (1) | ES2911040T3 (pt-PT) |
HR (1) | HRP20220472T1 (pt-PT) |
HU (1) | HUE058353T2 (pt-PT) |
LT (1) | LT3653620T (pt-PT) |
MX (1) | MX2020000349A (pt-PT) |
PL (1) | PL3653620T3 (pt-PT) |
PT (1) | PT3653620T (pt-PT) |
RS (1) | RS63156B1 (pt-PT) |
SI (1) | SI3653620T1 (pt-PT) |
WO (1) | WO2019012172A1 (pt-PT) |
ZA (1) | ZA202000727B (pt-PT) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114380751A (zh) * | 2020-03-30 | 2022-04-22 | 上海辉启生物医药科技有限公司 | 二氢化茚胺类衍生物、其制备方法和用途 |
WO2023102162A1 (en) | 2021-12-03 | 2023-06-08 | Tango Therapeutics, Inc. | Tgonovel hdac inhibitors and therapeutic use thereof |
CN114524799B (zh) * | 2022-03-11 | 2023-05-26 | 沈阳药科大学 | 一种hdac抑制剂及其制备方法和用途 |
EP4306106A1 (en) * | 2022-07-14 | 2024-01-17 | Universidade de Aveiro | Nitro-containing compounds, compositions and uses thereof |
CN115463215A (zh) * | 2022-07-26 | 2022-12-13 | 苏州大学 | Hdac9及其抑制剂的新用途 |
WO2024030659A1 (en) | 2022-08-05 | 2024-02-08 | Tango Therapeutics, Inc. | An hdac inhibitor for treating cancer with a modified stk11 activity or expression |
CN115304513A (zh) * | 2022-08-25 | 2022-11-08 | 湖北科技学院 | 具有抗炎活性的查尔酮类衍生物及其合成方法和应用 |
CN115368277B (zh) * | 2022-09-15 | 2024-03-29 | 华侨大学 | 一种含异羟肟酸结构的联苯类化合物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2626898A1 (en) | 2005-11-03 | 2007-05-18 | Christopher Hamblett | Substituted nicotinamide compounds |
CA2649861A1 (en) | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
JP2010531358A (ja) | 2007-06-27 | 2010-09-24 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体 |
WO2010144371A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
EP3204006A4 (en) * | 2014-10-08 | 2018-04-04 | Regenacy Pharmaceuticals, LLC | Induction of gata2 by hdac1 and hdac2 inhibitors |
WO2017004522A1 (en) * | 2015-07-02 | 2017-01-05 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibtors |
US9603950B1 (en) * | 2015-10-25 | 2017-03-28 | Institute Of Nuclear Energy Research | Compounds of imaging agent with HDAC inhibitor for treatment of Alzheimer syndrome and method of synthesis thereof |
-
2018
- 2018-07-09 BR BR112020000564-9A patent/BR112020000564A2/pt unknown
- 2018-07-09 ES ES18789777T patent/ES2911040T3/es active Active
- 2018-07-09 CN CN201880056722.5A patent/CN111051300B/zh active Active
- 2018-07-09 US US16/629,457 patent/US11241428B2/en active Active
- 2018-07-09 EP EP18789777.2A patent/EP3653620B9/en active Active
- 2018-07-09 HR HRP20220472TT patent/HRP20220472T1/hr unknown
- 2018-07-09 EA EA202090259A patent/EA039144B1/ru unknown
- 2018-07-09 HU HUE18789777A patent/HUE058353T2/hu unknown
- 2018-07-09 MX MX2020000349A patent/MX2020000349A/es unknown
- 2018-07-09 AU AU2018300123A patent/AU2018300123B2/en active Active
- 2018-07-09 WO PCT/ES2018/070491 patent/WO2019012172A1/es unknown
- 2018-07-09 PL PL18789777T patent/PL3653620T3/pl unknown
- 2018-07-09 PT PT187897772T patent/PT3653620T/pt unknown
- 2018-07-09 KR KR1020207003894A patent/KR102574135B1/ko active IP Right Grant
- 2018-07-09 JP JP2020523052A patent/JP7026787B2/ja active Active
- 2018-07-09 SI SI201830644T patent/SI3653620T1/sl unknown
- 2018-07-09 DK DK18789777.2T patent/DK3653620T3/da active
- 2018-07-09 CA CA3069273A patent/CA3069273A1/en active Pending
- 2018-07-09 LT LTEPPCT/ES2018/070491T patent/LT3653620T/lt unknown
- 2018-07-09 RS RS20220320A patent/RS63156B1/sr unknown
-
2020
- 2020-02-04 ZA ZA2020/00727A patent/ZA202000727B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020527173A5 (pt-PT) | ||
JP2019517487A5 (pt-PT) | ||
RU2704129C2 (ru) | Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения | |
EP1802606B1 (en) | Arylcarboxamides and their use as anti-tumor agents | |
TW202019900A (zh) | Ptpn11抑制劑 | |
JP2007534695A5 (pt-PT) | ||
IL278297B1 (en) | Transmutable heterocyclic ptpn11 inhibitors | |
JP2013533879A5 (pt-PT) | ||
HRP20220472T1 (hr) | Novi derivati heteroarilamida kao selektivni inhibitori histonskih deacetilaza 1 i 2 (hdac1-2) | |
JP2018520195A5 (pt-PT) | ||
JP2015516429A5 (pt-PT) | ||
RU2006112428A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
RU2020102453A (ru) | Фармацевтические композиции | |
JP2011511095A5 (pt-PT) | ||
JP6380777B2 (ja) | PI3K、mTOR阻害薬としての縮合キノリン化合物 | |
EP1697336B1 (en) | Aroylfuranes and aroylthiophenes suitable for the treatment of cancer | |
EP2473509A1 (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
JP2019507114A5 (pt-PT) | ||
JP2016525104A5 (pt-PT) | ||
RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
KR102169940B1 (ko) | 암, 바이러스성 감염 및 폐질환의 치료를 위한 인돌의 새로운 유도체 | |
JP6913955B2 (ja) | PI3K/mTOR阻害剤としての溶融キノリン化合物 | |
JP2010535204A5 (pt-PT) | ||
JP2009537606A5 (pt-PT) | ||
JP2006518726A5 (pt-PT) |